ARA-290 is a non-erythropoietic peptide derived from erythropoietin, designed to retain the tissue-protective and anti-inflammatory properties of erythropoietin without stimulating erythropoiesis. It has shown promise in various therapeutic applications due to its ability to modulate immune responses and protect tissues.
≥99% Purity
Third-Party Tested
COA Available
U.S. Manufactured
Quantity
In stock
Third-Party Verified Quality
≥99% purity verified through independent UHPLC-MS testing. Certificates of Analysis are available before purchase.
COAs available before purchase
U.S.-manufactured research-grade
Same-business-day U.S. dispatch for in-stock orders placed before 12 PM PT
Secure Checkout · Free shipping on orders over $400
ARA-290 is a non-erythropoietic peptide derived from erythropoietin, designed to retain the tissue-protective and anti-inflammatory properties of erythropoietin without its hematopoietic effects. This makes ARA-290 a promising candidate for research in various medical conditions where inflammation and tissue damage are prevalent.
One of the key areas of interest is its potential in treating neuropathic pain and metabolic disorders. In patients with type 2 diabetes, ARA-290 has shown promise in improving metabolic control and alleviating neuropathic symptoms, suggesting a role in both metabolic and nerve health.
ARA-290 is a novel peptide derived from erythropoietin (EPO) that has emerged as a promising therapeutic candidate across multiple disease areas. Unlike its parent molecule EPO, ARA-290 selectively activates tissue repair mechanisms without stimulating erythropoiesis, offering a potentially safer therapeutic profile. This synthetic peptide mimics EPO’s tissue-protective properties by specifically binding to the innate repair receptor (IRR), a distinct receptor complex that mediates cytoprotective and anti-inflammatory effects.
Initial preclinical and clinical studies have demonstrated ARA-290’s broad therapeutic potential, particularly in conditions characterized by inflammation, tissue damage, and neuropathy. Its unique mechanism of action involves modulating immune responses, promoting tissue repair, and protecting neural tissue, making it particularly relevant for diseases ranging from neurodegenerative conditions to metabolic disorders.
ARA-290 and Alzheimer’s Disease
ARA-290 has been investigated for its potential in Alzheimer’s disease (AD) therapy. It was found to decelerate the progression of AD-like pathology in early-onset models by modulating monocyte functions, specifically increasing the ratio of patrolling monocytes that help clear amyloid-β from the brain.1
Type 2 Diabetes and Neuropathy
ARA-290 has been evaluated in patients with type 2 diabetes, where it improved metabolic control and neuropathic symptoms. It was shown to enhance hemoglobin A1c levels and lipid profiles, as well as increase corneal nerve fiber density, indicating its potential in managing diabetes-related complications.2
Pain Management
In patients with sarcoidosis-associated small fiber neuropathy, ARA-290 has been effective in reducing neuropathic pain and improving quality of life. It increased corneal nerve fiber density and improved sensory pain thresholds, suggesting its role as a disease-modifying agent.3
ARA-290 also exhibits analgesic properties by targeting the TRPV1 channel, which is involved in pain sensation. This mechanism highlights its potential as a novel pain treatment option, integrating immune modulation with nociception.4
Autoimmune Neuropathies
In experimental autoimmune neuritis, ARA-290 has shown efficacy in suppressing inflammation and promoting nerve regeneration without inducing hematopoiesis, making it a candidate for treating autoimmune neuropathies.5
Tissue Repair
ARA-290 has been studied for its tissue-protective effects in critical limb ischemia, where it improved functional and histological outcomes in ischemic conditions, supporting its development as a therapeutic adjunct for ischemic injuries.6
References
Al-Onaizi, M., Thériault, P., Lecordier, S., Rivest, S., & ElAli, A. (2021). Early monocyte modulation by the non-erythropoietic peptide ARA 290 decelerates AD-like pathology progression. Brain, Behavior, and Immunity, 99, 363-382. https://doi.org/10.1016/j.bbi.2021.07.016.
Brines, M., Dunne, A., Van Velzen, M., Proto, P., Ostenson, C., Kirk, R., Petropoulos, I., Javed, S., Malik, R., Cerami, A., & Dahan, A. (2015). ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes. Molecular Medicine, 20, 658-666. https://doi.org/10.2119/molmed.2014.00215.
Heij, L., Niesters, M., Swartjes, M., Hoitsma, E., Drent, M., Dunne, A., Grutters, J., Vogels, O., Brines, M., Cerami, A., & Dahan, A. (2012). Safety and Efficacy of ARA 290 in Sarcoidosis Patients with Symptoms of Small Fiber Neuropathy: A Randomized, Double-Blind Pilot Study. Molecular Medicine, 18, 1430-1436. https://doi.org/10.2119/molmed.2012.00332.
Zhang, W., Yu, G., & Zhang, M. (2016). ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception. Peptides, 76, 73-79. https://doi.org/10.1016/j.peptides.2016.01.003.
Liu, Y., Luo, B., Han, F., Li, X., Xiong, J., Jiang, M., Yang, X., Wu, Y., & Zhang, Z. (2014). Erythropoietin-Derived Nonerythropoietic Peptide Ameliorates Experimental Autoimmune Neuritis by Inflammation Suppression and Tissue Protection. PLoS ONE, 9. https://doi.org/10.1371/journal.pone.0090942.
Yu, R., Baker, D., Abraham, D., & Tsui, J. (2014). Abstract 44: Tissue-Protective Effects of an Erythropoietin Derivative in in vitro and in vivo Models of Skeletal Muscle Ischemia. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/atvb.34.suppl_1.44.
Certificate of Analysis (COA)
A Certificate of Analysis (COA) is a document that verifies a compound’s identity, purity and quality through independent laboratory testing. Every compound from BioLongevity Labs is third-party tested, and its COA is published here, so researchers can review the testing record before a compound enters a protocol.
Each COA reports results from third-party laboratory analysis, including:
Ultra-high-performance liquid chromatography with mass spectrometry (UHPLC-MS) for purity, measured against a 98% or 99% specification depending on the compound
Mass identification for molecular confirmation and content quantitation
Endotoxin testing by Limulus amebocyte lysate (LAL) or recombinant Factor C (rFC) assay, depending on the laboratory
Visual and physical characterization of the finished material
How to Verify a COA Independently
You can check every certificate against the issuing laboratory’s own records, not just the copy hosted here. Verification does not depend on BioLongevity Labs.
AV Analytics certificates carry a search code. Scan the QR code on the certificate to open the laboratory’s verification page, or enter the search code at avanalytical.com/coa-search to pull the official record.
BioRegen reports of analysis carry a Report ID and a Validation Key. Scan the QR code on the certificate to open the official record, or quote both identifiers when you contact the laboratory at the address printed on the report.
SafeCert Labs issued a number of earlier certificates. Each one carries a COA number and the signature of the reporting chemist. Quote that number when you ask the laboratory to confirm it.
Older certificates from other laboratories list their own verification details on the document.
When a batch is sent to more than one laboratory, each certificate resolves at its own issuing laboratory. A researcher can then check the results against two unrelated sources.
These COAs come from independent certified laboratories, not in-house testing. That gives researchers a verifiable record of molecular integrity for each compound. All compounds are supplied for research use only.
Scientifically reviewed by Dr. Ky H. Le, MD. Dr. Le is a board-certified family medicine physician with over 20 years of clinical experience. Dr. Le validates the scientific accuracy of all technical content and research citations.
Disclaimer: For Research Purposes Only
This content is provided strictly for research purposes and does not constitute an endorsement or recommendation for the non-laboratory application or improper handling of peptides designed for research. The information, including discussions about specific peptides and their researched benefits, is presented for informational purposes only and must not be construed as health, clinical, or legal guidance, nor an encouragement for non-research use. Peptides described here are solely for use in structured scientific study by authorized individuals. We advise consulting with research experts, medical practitioners, or legal counsel prior to any decisions about obtaining or utilizing these peptides. The expectation of responsible, ethical utilization of this information for legitimate investigative and scholarly objectives is paramount. This notice is dynamic and governs all provided content on research peptides.
